MC1082: A Phase I/II Trial of Pomalidomide (CC-4047), Bortezomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 22 Mar 2018 Status changed from active, no longer recruiting to completed.
- 05 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 05 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.